EP Patent

EP4647126A3 — Stabilizing camptothecin pharmaceutical compositions

Assigned to Ipsen Biopharm Ltd · Expires 2026-02-11 · 0y expired

What this patent protects

Irinotecan phospholipid liposomes with improved storage stability are provided, with related methods of treatment and manufacture. The irinotecan liposomes can have reduced formation of lyso- phosphatidylcholine (lyso-PC) during storage, and prior to administration to a patient.

USPTO Abstract

Irinotecan phospholipid liposomes with improved storage stability are provided, with related methods of treatment and manufacture. The irinotecan liposomes can have reduced formation of lyso- phosphatidylcholine (lyso-PC) during storage, and prior to administration to a patient.

Drugs covered by this patent

Patent Metadata

Patent number
EP4647126A3
Jurisdiction
EP
Classification
—
Expires
2026-02-11
Drug substance claim
No
Drug product claim
No
Assignee
Ipsen Biopharm Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.